A case study on medical ethics revealed that when Merck conducted their Gardasil Human Papilloma Virus (HPV) clinical trials, they injected both the test and the placebo groups of girls and young women with a proprietary aluminum adjuvant which was extra potent, causing chronic disabling symptoms, despite the ‘informed consent’ information not mentioning the dangerous ingredient.
“The informed consent forms for Merck’s Gardasil vaccine trials appear to be seriously misleading, as a highly reactogenic adjuvant with a questionable safety record was described as an inactive placebo,” the case study said in the ‘Conclusion’ section.
An adjuvant is a vaccine ingredient that agitates the immune system into eliciting an immune response to the vaccination agent, in this case HPV.
“Merck used their proprietary amorphous aluminum hydroxyphosphate sulfate (AAHS) adjuvant as the “placebo”. The V501-018 trial however, did not use a saline placebo either, but rather the Gardasil vaccine’s carrier solution which includes L-histidine, polysorbate 80, sodium borate and residual yeast protein which is a potential allergen [7,8]. Moreover, only 1,781 children between 9 and 15 years of age were included in this trial; both male and female who were randomized in a 2:1 ratio to receive either Gardasil or the “placebo” [8]. By contrast, the largest pre-licensure Gardasil trial V501-015 (the FUTURE II trial), recruited 12,167 subjects, all females between 15 and 26 years of age, who were randomized in a 1:1 ratio to receive either Gardasil or the AAHS injection [9],” the case study said in section 1 of the ‘Background’ section.
The researchers said that four years after vaccination, the test subjects had “reduced HPV-related carcinoma in situ, external genital lesions, and HPV-related treatment procedures. However, the HPV vaccines increased serious nervous system disorders and general harms.” They went on to detail the specifics.
Hellbound and Down 